Skip Navigation LinksHome > January 2008 - Volume 51 - Issue 1 > Anticoagulant Activity of Captopril
Journal of Cardiovascular Pharmacology:
doi: 10.1097/FJC.0b013e31815d1d3e
Original Article

Anticoagulant Activity of Captopril

Brecher, Arthur S PhD; Murrey, Sarah J; Gray, Kelly D BS; Poulimenos, James N BS

Collapse Box


The antihypertensive drug, captopril, exerted an anticoagulant effect upon clotting time as followed by prothrombin time (PT) and activated partial thromboplastin time (APTT), with prolongation of clotting observed at 4.25 × 10−3 M and 4 × 10−3 M captopril for PT and APTT, respectively, using commercial level I plasma. Utilizing level III plasmas, PT and APTT values were both prolonged by 4.25 × 10−3 M captopril. Captopril (6 × 10−3 M) also directly prolonged the clotting of thrombin in a thrombin-factor II-deficient plasma assay, whereas 5 × 10−3 M captopril inhibited FIIDP in a thrombin-FIIDP assay. In thrombin-fibrinogen assays, pre-incubation of 2.5 × 10−3 M captopril with fibrinogen also prolonged clotting time, whereas 3 × 10−3 M captopril prolonged thrombin activity. These data suggest that thiol-disulfide exchange permits reduction of disulfide groups in thrombin and fibrinogen, altering their tertiary structure and physiological function. Lisinopril at a pharmacological 10−2 M also prolonged APTT, although it lacks a thiol group. Polylysine (1k-4k) affected a prolongation of APTT at 6.7 × 10−6 M, suggesting inhibition of clotting by a different mechanism.

© 2008 Lippincott Williams & Wilkins, Inc.

Follow Us!


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.